Holen Sie sich die Stockscreener-App
0.86
3.10%
-0.0275
Handel nachbörslich:
.89
0.03
+3.49%
Schlusskurs vom Vortag:
$0.8875
Offen:
$0.8609
24-Stunden-Volumen:
80,165
Relative Volume:
0.42
Marktkapitalisierung:
$65.26M
Einnahmen:
$8.23M
Nettoeinkommen (Verlust:
$-32.49M
KGV:
-1.6226
EPS:
-0.53
Netto-Cashflow:
$-19.91M
1W Leistung:
+1.84%
1M Leistung:
-0.12%
6M Leistung:
-20.37%
1J Leistung:
-32.81%
1-Tages-Spanne:
$0.8397
$0.8939
1-Wochen-Bereich:
$0.8397
$0.9137
52-Wochen-Spanne:
$0.7001
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
Firmenname
Clearside Biomedical Inc
Sektor
Branche
Telefon
678-270-3631
Adresse
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Vergleichen Sie CLSD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.86 | 65.26M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-15 | Fortgesetzt | Wedbush | Outperform |
| 2021-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-09 | Herabstufung | Needham | Buy → Hold |
| 2018-11-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2018-11-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2018-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-06 | Bestätigt | Needham | Buy |
| 2017-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-10-24 | Bestätigt | Stifel | Buy |
Alle ansehen
Clearside Biomedical Inc Aktie (CLSD) Neueste Nachrichten
Clearside Biomedical Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $726,000 Position in Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical to Participate in a Fireside Chat at the Ci - GuruFocus
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference - GlobeNewswire
Clearside Biomedical Showcases Revolutionary Eye Treatment Platform at Major Healthcare Conference - Stock Titan
Clearside Biomedical (NASDAQ:CLSD) Raised to “Hold” at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
JMP maintains $5 price target on Clearside Biomedical stock By Investing.com - Investing.com Canada
Form DEFA14A Clearside Biomedical, - StreetInsider
CLSD Stock Sees Surge of Approximately 14.80% in Last Five Days - knoxdaily.com
Clearside Biomedical’s (CLSD) Buy Rating Reiterated at Needham & Company LLC - Defense World
Clearside Biomedical stock hits 52-week low at $0.77 - Investing.com
Clearside Biomedical at Needham Conference: Strategic Developments in Retinal Therapies - Investing.com Canada
HC Wainwright Analysts Lift Earnings Estimates for CLSD - Defense World
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Strategic Updates Expected: Clearside Biomedical CEO Takes Stage at Major Healthcare Conference - Stock Titan
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge - Investing.com Australia
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge By Investing.com - Investing.com South Africa
Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD - MSN
Clearside Biomedical (NASDAQ:CLSD) Earns “Buy” Rating from Chardan Capital - Defense World
Needham & Company LLC Has Lowered Expectations for Clearside Biomedical (NASDAQ:CLSD) Stock Price - Defense World
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations - Yahoo
JMP reiterates Clearside Biomedical stock with $5 target By Investing.com - Investing.com Canada
Clearside Biomedical’s Positive Earnings Call Highlights Progress and Challenges - TipRanks
Stifel maintains Clearside Biomedical buy rating, $8 target By Investing.com - Investing.com UK
Clearside Biomedical (CLSD) Prepares for Phase 3 Trials, Seeks F - GuruFocus
Clearside Biomedical Reports Net Loss for Fourth Quarter and Full Year 2024 - VisionMonday.com
Clearside Biomedical Reports 2024 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast - Investing.com India
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings: EPS Matches Es - GuruFocus
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Clearside Biomedical Reports 2024 Financial Results and Updates - TipRanks
Clearside Biomedical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Clearside Biomedical earnings matched, revenue topped estimates - Investing.com
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Reports 95% Revenue Decline, But Secures Critical FDA Agreement for Phase 3 Trial - Stock Titan
Exploring Clearside Biomedical's Earnings Expectations - Benzinga
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - The Manila Times
Clearside Biomedical Announces Six Abstracts Accepted for - GlobeNewswire
Game-Changing Eye Treatment Data: Clearside to Present Phase 2b Results at ARVO 2025 - Stock Titan
Clearside Biomedical Presents Comparative Data on CLS-AX for Wet AMD at 2025 Wet AMD & Diabetic Eye Disease Summit - Nasdaq
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet - GlobeNewswire
Clearside's Revolutionary Eye Treatment Platform Targets $12B Wet AMD Market After FDA Green Light - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Downgraded to Sell Rating by StockNews.com - Defense World
Finanzdaten der Clearside Biomedical Inc-Aktie (CLSD)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):